MEA Technetium-99m Market to Witness Increasing Revenue Growth During the Forecast Period 2020–2027
Over the years, investments in the production of molybdenum-99 have increased significantly. Molybdenum-99 decays by emitting a beta particle and when around 88% of it decayed, it produces technetium-99m. As a result of this, key players are focused on scaling the production Mo-99. Thus, such factors can potentially augment growth of the MEA technetium-99m market in the near future. Recently, in January 2021, NorthStar Medical Radioisotopes LLC received the U.S. Food and Drug Administration (FDA) approval for the process molybdenum-99 from concentrated Mo-98 and related software upgrades for its RadioGenix System technetium-99m (Tc-99m) generator.
The first step in using this particular type of mineral is to generate a high-quality Molybdenum 99m generator. This generator must contain at least six milligrams of technetium-99m. The highest quality generators can be found online and through reputable medical supply companies. Technetium-99m finds diverse applications, typically as a medical radioisotope. Over the years, the prevalence of congenital heart disease (CHD) has increased worldwide. As per the National Center for Biotechnology Information (NCBI), in 2019, CHD incidence in Saudi Arabia was reported to be between 2.1 and 10.7 per 1,000 persons. Such rising incidence of CHD has necessitated adequate treatment options. Therefore, these factors can stimulate growth of the MEA technetium-99m market.
Read More: https://bit.ly/3ArNNd5
Comments
Post a Comment